MediWound Ltd. (MDWD) – What Are Brokerages Saying About This Stock?

Shares of MediWound Ltd. (NASDAQ:MDWD) have been given an average recommendation of “Moderate Buy” by the five ratings firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $33.00.

MDWD has been the subject of a number of research reports. Alliance Global Partners reiterated a “buy” rating on shares of MediWound in a research report on Wednesday, September 16th. Weiss Ratings lowered shares of MediWound from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, September 8th. Oppenheimer reissued an “outperform” rating and issued a $30.00 price target (down from $32.00) on shares of MediWound in a research report on Friday, August 14th. Wall Street Zen upgraded shares of MediWound from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 26th. Finally, TD Cowen restated a “buy” rating on shares of MediWound in a research note on Thursday, September 24th.

Insider Transactions at MediWound

In other MediWound news, COO Shmuel Hess sold 3,958 shares of the business’s stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $12.92, for a total transaction of $51,137.36. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 9.20% of the stock is owned by insiders.

Hedge Funds Weigh In On MediWound

An institutional investor recently raised its stake in MediWound stock. Russell Investments Group Ltd. lifted its stake in shares of MediWound Ltd. (NASDAQ:MDWD) by 750.3% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 57,494 shares of the biopharmaceutical company’s stock after purchasing an additional 50,732 shares during the quarter. Russell Investments Group Ltd. owned 0.44% of MediWound worth $792,000 as of its most recent SEC filing. 46.83% of the stock is currently owned by institutional investors and hedge funds.

MediWound Trading Down 2.1%

MDWD stock opened at $13.82 on Thursday. The stock has a fifty day moving average of $13.21 and a 200-day moving average of $15.10. MediWound has a fifty-two week low of $11.80 and a fifty-two week high of $19.70.

MediWound (NASDAQ:MDWD) last announced its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.01). The firm had revenue of $3.09 million during the quarter, compared to the consensus estimate of $2.59 million. MediWound had a negative net margin of 170.10% and a negative return on equity of 47.24%. Analysts anticipate that MediWound will post -2.37 earnings per share for the current fiscal year.

About MediWound

MediWound Ltd. (NASDAQ: MDWD) is a commercial-stage biotechnology company focused on developing and marketing innovative enzymatic therapies for complex wounds. The company’s products are designed to support the removal of damaged tissue and improve wound management, with an emphasis on severe burns and hard-to-heal chronic wounds. MediWound’s lead product, NexoBrid, is a bromelain-based topical biological product used for the enzymatic removal of eschar, or dead tissue, from deep partial-thickness and full-thickness thermal burns.